NDAORALTABLETPriority Review
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor) by Vertex Pharmaceuticals is chloride channel activation potentiators [moa]. Approved for cystic fibrosis transmembrane conductance regulator potentiator [epc]. First approved in 2024.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALYFTREK is a triple-combination oral tablet containing vanzacaftor, tezacaftor, and deutivacaftor, approved December 2024 for cystic fibrosis. It works by activating chloride channels and potentiating the cystic fibrosis transmembrane conductance regulator (CFTR) to improve lung function. This represents Vertex's latest-generation modulator combination targeting CF patients with specific CFTR mutations.
Growth16.6 years to LOE
Early-stage growth product with significant runway; commercial teams should expect scaling of market access, reimbursement, and patient support infrastructure over the next 2-3 years.
Mechanism of Action
Chloride Channel Activation Potentiators
Pharmacologic Class:
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
Started Sep 2009
140 enrolled
Cystic Fibrosis
Career Relevance
ALYFTREK represents a growth-stage launch opportunity in a niche but high-value CF market dominated by Vertex; career roles will center on market penetration, payer negotiation, and patient education. Professionals joining the ALYFTREK team benefit from a established disease indication, strong patent protection, and Vertex's proven CF commercial infrastructure.
Brand Manager
Worked on ALYFTREK at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.